Please assess the completion status of the following clinical trial:

Trial Title: FARE Peanut SLIT and Early Tolerance Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from participant's parent/guardian.~* Age 12-48 months of either sex, any race, any ethnicity.~* A peanut allergy diagnosis with a convincing clinical history of peanut allergy and a serum peanut-specific IgE \[UniCAP\] \> 0.35 kUA/L AND a positive skin prick test to peanut (\>3 mm than the negative control) OR are sensitized to peanut (based on a serum IgE \[UniCAP\] to peanut of \> 5 kUA/L) AND a positive skin prick test to peanut (\> 3 mm than the negative control) and no known history of ingestion of peanut.~* A positive DBPCFC to 1000 mg of peanut at enrollment.~Exclusion Criteria:~* History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or peripheral capillary oxygen saturation (SpO2) \< 92% at any stage, hypotension, confusion, collapse or loss of consciousness).~* Participation in any interventional study for the treatment of food allergy in the past 6 months.~* Known oat, wheat, or glycerin allergy.~* Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease.~* Severe asthma (2007 NHLBI Criteria Steps 5 or 6 - Appendix 2).~* Inability to discontinue antihistamines for skin testing and DBPCFCs.~* Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year.~* Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers.~* Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Peanut (liquid peanut extract) SLIT (Type: EXPERIMENTAL): After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
- Placebo Glycerin SLIT (Type: PLACEBO_COMPARATOR): After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).